{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:03:50Z","timestamp":1791417830156,"version":"4.3.3"},"reference-count":64,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024018","name":"Programa de Desarrollo de Las Ciencias B\u00e1sicas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Chem."],"abstract":"<jats:p>Antimalarial drugs based on quinolines have been widely used as leishmanicidal agents for either cutaneous or visceral leishmaniasis models. Herein, we showed the leishmanicidal response against <jats:italic>in vitro<\/jats:italic> models of different <jats:italic>Leishmania<\/jats:italic> spp. and against <jats:italic>in vivo<\/jats:italic> models of eleven key antimalarials, including chloroquine, sitamaquine, amodiaquine, mefloquine, quinine, primaquine, hydroxychloroquine, tafenoquine, quinacrine and moxipraquine. Mechanistic studies and advances in clinical treatment are also discussed. This mini-review aims to show the state of the art in using antimalarial drugs to discover alternative therapies for leishmaniasis treatment.<\/jats:p>","DOI":"10.3389\/fchem.2025.1608340","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:46:33Z","timestamp":1748583993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["A comprehensive revision on the use of quinoline antimalarial drugs as leishmanicidal agents"],"prefix":"10.3389","volume":"13","author":[{"given":"Romina E.","family":"Avanzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Garc\u00eda Li\u00f1ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noris","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel H.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"48","DOI":"10.26452\/ijrps.v15i4.4720","article-title":"Development and evaluation of an oral quinine sulphate sustained release formulation for the management of visceral leishmaniasis","volume":"15","author":"Allotey-Babington","year":"2024","journal-title":"Int. J. Res. Pharm. Sci."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e202","DOI":"10.1093\/cid\/ciw670","article-title":"Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of America (IDSA) and the American society of tropical medicine and hygiene (ASTMH)","volume":"63","author":"Aronson","year":"2016","journal-title":"Clin. Inf. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0035-9203(80)90010-3","article-title":"The activity against Trypanosoma cruzi and cutaneous leishmaniasis, and toxicity, of moxipraquine (349C59)","volume":"74","author":"Beveridge","year":"1980","journal-title":"Trans. Roy. Soc. Trop. Med. Hyg."},{"key":"B4","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.bioorg.2018.10.053","article-title":"Synthesis and biological evaluation of new quinoline derivatives as antileishmanial and antitrypanosomal agents","volume":"83","author":"Chanquia","year":"2019","journal-title":"Bioorg. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1017\/s0031182017000993","article-title":"Repurposing as a strategy for the discovery of new anti-leishmanials: the-state-of-the-art","volume":"145","author":"Chartlon","year":"2017","journal-title":"Parasitology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"106","DOI":"10.13171\/mjc.1.3.2011.26.09.22","article-title":"Amodiaquine analogs. Synthesis and anti-leishmanial activity","volume":"1","author":"Coimbra","year":"2011","journal-title":"Mediterr. J. Chem."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1586044","DOI":"10.3389\/fchem.2025.1586044","article-title":"Metal complexes based on quinoline for development of leishmanicidal agents: structure and mechanism of action","volume":"13","author":"Del Carpio","year":"2025","journal-title":"Front. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1553975","DOI":"10.3389\/fchem.2025.1553975","article-title":"4-Aminoquinoline: a comprehensive review of synthetic strategies","volume":"13","author":"Delgado","year":"2025","journal-title":"Front. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1021\/jm0401006","article-title":"Antileishmanial pyrazolopyridine derivatives: synthesis and structure\u2212activity relationship analysis","volume":"47","author":"De Mello","year":"2004","journal-title":"J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"685","DOI":"10.4269\/ajtmh.2001.65.685","article-title":"Phase II trial of WR6026, an orally administrated 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi","volume":"65","author":"Dietze","year":"2001","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B64","year":"2023"},{"key":"B11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.bbamem.2006.07.003","article-title":"Interaction of sitamaquine with membrane lipids of Leishmania donovani promastigotes","volume":"1768","author":"Due\u00f1as-Romero","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"B12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.51253\/pafmj.v71i1.3187","article-title":"Comparison of oral chloroquine with systemic meglumine antimoniate in treatment of cutaneous leishmaniasis","volume":"71","author":"Farooq","year":"2021","journal-title":"Pak. Armed. Forces Med. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1590\/s0037-86822000000400008","article-title":"Therapeutic trial in experimental tegumentary leishmaniasis caused by Leishmania amazonensis: a comparative study between mefloquine and aminosidine","volume":"33","author":"Galv\u00e3o","year":"2000","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1211\/jpp.58.8.0004","article-title":"In vitro and in vivo studies on a topical formulation of sitamaquine dihydrochloride for cutaneous leishmaniasis","volume":"58","author":"Garnier","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5071","DOI":"10.1016\/j.ejmech.2009.09.012","article-title":"A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity","volume":"44","author":"Guglielmo","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"B16","first-page":"260","article-title":"Intralesional versus oral chloroquine in cutaneous leishmaniasis: comparison of outcome, duration of treatment and total dose of drug","volume":"26","author":"Hanif","year":"2016","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"B17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.biopha.2014.08.009","article-title":"Sitamaquine-resistance in Leishmania donovani affects drug accumulation and lipid metabolism","volume":"68","author":"Imberta","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.4269\/ajtmh.2005.73.1005","article-title":"A phase II dose-ranging study of sitamaquine for treatment of visceral leishmaniasis in India","volume":"73","author":"Jha","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B19","first-page":"95","article-title":"Chloroquine in cutaneous leishmaniasis","volume":"17","author":"Khan","year":"2007","journal-title":"J. Pak. Assoc. Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"751","DOI":"10.4269\/ajtmh.1978.27.751","article-title":"The antileishmanial activity of lepidines","volume":"27","author":"Kinnamon","year":"1978","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-323-91124-5.00012-6","article-title":"Leishmaniasis: an overview","volume-title":"Developments in immunology, visceral leishmaniasis","author":"Kumar","year":"2021"},{"key":"B22","doi-asserted-by":"publisher","first-page":"106661","DOI":"10.1016\/j.actatropica.2022.106661","article-title":"Amphotericin B: a drug of choice for visceral leishmaniasis","volume":"235","author":"Kumari","year":"2022","journal-title":"Act. Trop."},{"key":"B23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1590\/S0037-86821999000500010","article-title":"Mefloquina no tratamento da leishmaniose cut\u00e2nea em uma \u00e1rea end\u00eamica de Leishmania (Viannia) braziliensis","volume":"32","author":"Laguna-Torres","year":"1999","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"B24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2149\/tmh1973.23.151","article-title":"Oral treatment of new world cutaneous leishmaniasis with anti-malarial drugs in Ecuador: a preliminary clinical trial","volume":"23","author":"Landires","year":"1995","journal-title":"Jap. J. Trop. Med. Hyg."},{"key":"B25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1111\/j.1550-7408.1983.tb01421.x","article-title":"Fine structure alterations in Leishmania tropica within macro phages exposed to antileishmanial drugs in vitro","volume":"30","author":"Langreth","year":"1983","journal-title":"J. Protozool."},{"key":"B26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1051\/parasite\/2011182115","article-title":"Sitamaquine as a putative antileishmanial drug candidate: from the mechanism of action to the risk of drug resistance","volume":"18","author":"Loiseau","year":"2011","journal-title":"Parasite"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1128\/aac.00964-08","article-title":"Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocal cisomes","volume":"52","author":"L\u00f3pez-Mart\u00edn","year":"2008","journal-title":"Antimicr. Agent. Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"403","DOI":"10.29271\/jcpsp.2019.05.403","article-title":"Comparing the efficacy of oral chloroquine versus oral tetracycline in the treatment of cutaneous leishmaniasis","volume":"29","author":"Malik","year":"2019","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"B29","doi-asserted-by":"publisher","first-page":"8965","DOI":"10.1007\/s00253-020-10856-w","article-title":"Recent advances and new strategies on leishmaniasis treatment","volume":"104","author":"Mendes","year":"2020","journal-title":"Appl. Microbiol. Biotech."},{"key":"B30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.actatropica.2013.11.003","article-title":"Combination therapy with nitazoxanide and amphotericin B, Glucantime\u00ae, miltefosine and sitamaquine against Leishmania (Leishmania) infantum intracellular amastigotes","volume":"130","author":"Mesquita","year":"2014","journal-title":"Acta Trop."},{"key":"B31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12982-024-00247-1","article-title":"Classical and innovative drugs for the treatment of Leishmania infections","volume":"21","author":"Mota","year":"2024","journal-title":"Discov. Public Health"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/s0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.7555\/JBR.29.20140072","article-title":"In vitro activity and in vivo efficacy of a combination therapy of diminazene and chloroquine against murine visceral leishmaniasis","volume":"29","author":"Mwololo","year":"2015","journal-title":"J. Biomed. Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4236\/aim.2016.61002","article-title":"Screening of anti-infectives against Leishmania donovani","volume":"6","author":"Nettey","year":"2016","journal-title":"Adv. Microbiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e01285","DOI":"10.1016\/j.sciaf.2022.e01285","article-title":"Oral amodiaquine microparticles repurposed for the treatment of visceral leishmaniasis","volume":"17","author":"Nettey","year":"2022","journal-title":"Sci. Afr."},{"key":"B36","unstructured":"Adverse effects of antileishmanial medicines\n          \n          \n          2022"},{"key":"B37","first-page":"18","article-title":"Intralesional chloroquine in cutaneous leishmaniasis","volume":"15","author":"Noor","year":"2005","journal-title":"J. Pak. Assoc. Dermatol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"107143","DOI":"10.1016\/j.actatropica.2024.107143","article-title":"Quinine and chloroquine: potential preclinical candidates for the treatment of tegumentary Leishmaniasis","volume":"252","author":"Pejara-Rossi","year":"2024","journal-title":"Acta Trop."},{"key":"B39","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00436-012-3183-4","article-title":"Antiprotozoal activity of ferroquine","volume":"112","author":"Pomel","year":"2012","journal-title":"Parasitol. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.1016\/j.bmc.2015.03.029","article-title":"New heterocyclic compounds: synthesis and antitrypanosomal properties","volume":"23","author":"Pomel","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"110333","DOI":"10.1016\/j.cbi.2022.110333","article-title":"Exploring the repositioning of the amodiaquine as potential drug against visceral leishmaniasis: the in vitro effect against Leishmania infantum is associated with multiple mechanisms, involving mitochondria dysfunction, oxidative stress and loss of cell cycle control","volume":"371","author":"Ribeiro-Antinarelli","year":"2023","journal-title":"Chem. Biol. Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1099\/jmm.0.058115-0","article-title":"Activity of antimalarial drugs in vitro and in a murine model of cutaneous leishmaniasis","volume":"62","author":"Rocha","year":"2013","journal-title":"J. Med. Microbiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1527946","DOI":"10.3389\/fchem.2024.1527946","article-title":"4-Aminoquinoline as a privileged scaffold for the design of leishmanicidal agents: structure-property relationships and key biological targets","volume":"12","author":"Romero","year":"2025","journal-title":"Front. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1800281","DOI":"10.1002\/ardp.201800281","article-title":"Identification of dehydroxy isoquine and isotebuquine as promising antileishmanial agents","volume":"352","author":"Romero","year":"2019","journal-title":"Arch. Pharm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jac\/dkq542","article-title":"In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani","volume":"66","author":"Seifert","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/clinids\/19.6.1034","article-title":"Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis","volume":"19","author":"Sherwood","year":"1994","journal-title":"Clin. Inf. Dis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/21678707.2024.2335248","article-title":"Current and emerging therapies for the treatment of leishmaniasis","volume":"12","author":"Sundar","year":"2024","journal-title":"Exp. Opin. Orphan Drugs"},{"key":"B49","first-page":"865","article-title":"Identification and quantitation of human urinary metabolites of a candidate 8-aminoquinoline antileishmanial drug (WR 6026)","volume-title":"Federation proceedings","author":"Theoharides","year":"1987"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e56785","DOI":"10.7759\/cureus.56785","article-title":"Comparative efficacy of intralesional chloroquine with intralesional meglumine antimoniate in the treatment of cutaneous leishmaniasis","volume":"16","author":"Ullah","year":"2024","journal-title":"Cureus"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5112","DOI":"10.1128\/AAC.00557-13","article-title":"N-cinnamoylated aminoquinolines as promising antileishmanial agents","volume":"57","author":"Vale-Costa","year":"2013","journal-title":"Antimicr. Agent. Chemother."},{"key":"B52","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1128\/AAC.00873-12","article-title":"Peptidomimetic and organometallic derivatives of primaquine active against Leishmania infantum","volume":"56","author":"Vale-Costa","year":"2012","journal-title":"Antimicr. Agent. Chemother."},{"key":"B53","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1042\/bj2840463","article-title":"Ca2+ transport by digitonin-permeabilized Leishmania donovani. Effects of Ca2+, pentamidine and WR-6026 on mitochondrial membrane potential in situ","volume":"284","author":"Vercesi","year":"1992","journal-title":"Biochem. J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0014-5793(00)01531-3","article-title":"Presence of a Na+\/H+ exchanger in acidocalcisomes of Leishmania donovani and their alkalization by anti-leishmanial drugs","volume":"473","author":"Vercesi","year":"2000","journal-title":"FEBS Lett."},{"key":"B55","doi-asserted-by":"crossref","first-page":"871","DOI":"10.4269\/ajtmh.2005.73.871","article-title":"A phase II dose-increasing study of sitamaquine for treatment of visceral leishmaniasis in Kenya","volume":"73","author":"Wasunna","year":"2005","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B56","doi-asserted-by":"publisher","first-page":"e00358","DOI":"10.1128\/AAC.00358-17","article-title":"Efficacy of paromomycin-chloroquine combination therapy in experimental cutaneous leishmaniasis","volume":"61","author":"Wijnant","year":"2017","journal-title":"Antimicrob. Agent. Chemother."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/jac\/dkp130","article-title":"Quinacrine and a novel apigenin dimer can synergistically increase the pentamidine susceptibility of the protozoan parasite Leishmania","volume":"63","author":"Wong","year":"2009","journal-title":"J. Antimicr. Chemother."},{"key":"B58","volume-title":"Leishmaniasis","year":"2023"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1571067","DOI":"10.3389\/fchem.2025.1571067","article-title":"The quinoline framework and related scaffolds in natural products with anti-Leishmania properties","volume":"13","author":"Yaluff","year":"2025","journal-title":"Front. Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1128\/AAC.00985-10","article-title":"Antileishmanial and antitrypanosomal activities of the 8-aminoquinoline tafenoquine","volume":"54","author":"Yardley","year":"2010","journal-title":"Antimicr. Agent. Chemother."},{"key":"B61","first-page":"270","article-title":"Response to treatment of cutaneous leishmaniasis with intralesional chloroquine vs intralesional meglumine antimoniate","volume":"21","author":"Yasmin","year":"2011","journal-title":"J. Pak. Assoc. Dermatol."},{"key":"B62","first-page":"1446","article-title":"Sitamaquine (GlaxoSmithKline\/Walter reed army institute)","volume":"3","author":"Yeates","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"B63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.15416\/pcpr.v5i3.29380","article-title":"Anti-malarial drugs as potential inhibitors of Leishmania glycolytic enzymes: development of new anti-leishmanial agents","volume":"5","author":"Yousef","year":"2020","journal-title":"Pharmacol. Clin. Pharm. Res."}],"container-title":["Frontiers in Chemistry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2025.1608340\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:46:37Z","timestamp":1748583997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fchem.2025.1608340\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":64,"alternative-id":["10.3389\/fchem.2025.1608340"],"URL":"https:\/\/doi.org\/10.3389\/fchem.2025.1608340","relation":{},"ISSN":["2296-2646"],"issn-type":[{"value":"2296-2646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"article-number":"1608340"}}